Print
Email
Print Edition StoriesThursday, June 12, 2008
Molecular Insight studies prostate cancer detection
By Mass High Tech Staff
Molecular Insight Pharmaceuticals Inc. has begun a Phase 1 clinical trial to test molecular radiopharmaceutical candidates’ ability to detect metastatic prostate cancer.
The molecules, MIP-1072 and MIP-1095, seek out prostate-specific membrane antigen, a protein existing in the presence of prostate cancer cells.
Up to 12 study participants will take either MIP-1072 or MIP-1095 in one dose, followed by a dose of the opposite molecule two weeks later. The study required Molecular Insight to submit an Investigational New Drug application to the U.S. Food and Drug Administration.
The second-leading cause of cancer death in men is prostate cancer, according to the National Institutes of Health.
Cambridge-based Molecular Insight (Nasdaq: MIPI) specializes in the development of radiotherapeutics and molecular-imaging agents in the fields of oncology and cardiology. Founded in 1997 (as Imaging Biopharmaceuticals Inc.), the company reported a 2007 net loss of $60 million on $730,000 net revenue.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
